Can Wegovy (semaglutide) cause hot flashes and extreme fatigue?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Wegovy Cause Hot Flashes and Extreme Fatigue?

Yes, Wegovy (semaglutide) can cause extreme fatigue, which is listed as a common side effect in the FDA label, but hot flashes are not a recognized direct adverse effect of the medication itself.

Fatigue as a Documented Side Effect

Tiredness (fatigue) is explicitly listed among the most common side effects of Wegovy in the FDA-approved prescribing information 1. This is a well-established adverse effect that patients should be counseled about when initiating therapy.

Clinical Evidence for Fatigue

A 2025 case report documented semaglutide-induced sarcopenia in a 74-year-old patient who experienced progressive fatigue over 2 years, with significant decline in walking endurance and an 8 kg weight loss 2. The patient's fatigue improved after reducing the semaglutide dose and implementing a muscle-strengthening exercise program. This case highlights that fatigue may be related to muscle mass loss, particularly in older adults, and is potentially dose-dependent.

Hot Flashes: Not a Direct Side Effect

Hot flashes are not listed in the FDA label as a side effect of Wegovy 1. However, there is one important caveat:

Indirect Mechanism in Specific Populations

A 2025 case report described worsening vasomotor symptoms (hot flashes) in a 51-year-old postmenopausal woman taking oral estrogen therapy who started semaglutide 3. The mechanism appears to be:

  • Semaglutide delays gastric emptying (a well-documented pharmacologic effect) 4
  • This delayed gastric emptying may temporarily decrease absorption of oral estrogen
  • Reduced estrogen absorption led to breakthrough vasomotor symptoms
  • Symptoms resolved when semaglutide dose titration was slowed

This is not a direct effect of semaglutide causing hot flashes, but rather an indirect drug interaction affecting estrogen absorption in patients taking oral hormone therapy.

Clinical Management Algorithm

For Fatigue:

  1. Confirm it's related to Wegovy by reviewing timing of symptom onset relative to drug initiation or dose escalation
  2. Assess for muscle loss - particularly important in older adults or those with rapid weight loss
  3. Consider dose reduction if fatigue is severe or impacting quality of life 2
  4. Implement resistance training and adequate protein intake to preserve muscle mass
  5. Rule out other causes: anemia, thyroid dysfunction, depression, or dehydration from GI side effects 1

For Hot Flashes:

  1. If the patient is NOT on oral estrogen therapy: hot flashes are likely unrelated to Wegovy - investigate other causes (menopause, thyroid disease, other medications)
  2. If the patient IS on oral estrogen therapy:
    • Consider that semaglutide may be impairing estrogen absorption 3
    • Slow the semaglutide dose titration
    • Consider switching to transdermal estrogen (patch/gel) which bypasses first-pass metabolism and is unaffected by gastric emptying
    • Monitor symptom resolution over 2-4 weeks

Important Caveats

  • The gastric emptying effect is most pronounced during initial dosing and dose escalations, and may improve with prolonged GLP-1 receptor stimulation 3
  • Dehydration from GI side effects (nausea, vomiting, diarrhea - occurring in up to 25% and 10% of patients respectively) 5 can worsen fatigue and should be addressed with adequate fluid intake 1
  • Weight loss itself can contribute to fatigue if too rapid or associated with inadequate nutrition
  • Fatigue severe enough to impact daily function warrants dose adjustment or discontinuation

References

Related Questions

How many milliliters of a semaglutide formulation containing 2.5 mg per milliliter are needed to prescribe a 3 mg dose?
What are alternative options to Ozempic (semaglutide) if it is ineffective?
What alternative medication can replace oral semaglutide (Rybelsus) 14 mg daily for a patient when it is no longer available?
What New England Journal of Medicine (NEJM) studies are available on semaglutide (Ozempic)?
Can semaglutide be used in an obese patient with Graves disease who is being treated with methimazole?
Will oral corticosteroids relieve muscle-related pain associated with radiculopathy?
In an asymptomatic patient whose hormone panel was drawn under traumatic and stressful conditions and shows markedly elevated ACTH, elevated cortisol, and DHEA‑S at the upper limit of normal, what is the appropriate management?
What is the recommended evaluation and management for a young adult female attorney with persistent fatigue and non‑restorative sleep despite 8–9 hours of sleep, a 60‑minute sleep latency, night sweats, evening energy surge, reflux‑related cough, occasional bruxism, on escitalopram (Lexapro) and bupropion (Wellbutrin), Epworth Sleepiness Scale 12, and no evidence of obstructive sleep apnea?
What is the ICD‑10‑CM code for a closed fracture of the head of the radius?
Is a serum osmolality of 278.3 mOsm/kg considered low, and what should be the next steps?
When is a febrile seizure considered complex?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.